RBC Capital analysts upgraded shares of Cardiome Pharma Corp. (NASDAQ: CRME) from a “sector perform” rating to an “outperform” rating. They now have a $8.00 price target on the stock.
Cardiome Pharma Corp:( NASDAQ: CRME) gained on analyst's upgrade !
0 comments